<p>The analysis of circulating cell free DNA is an important tool for the analysis of tumor resistance, tumor heterogeneity, detection of minimal residual disease and detection of allograft rejection in kidney or heart transplant patients. The proper use of this technique is important, and starts with considering pre-analytic aspects. The current paper addresses some important technical considerations to ensure the proper and harmonized use of cfDNA techniques.</p>

doi.org/10.1016/j.cca.2021.05.033, hdl.handle.net/1765/135862
Clinica Chimica Acta
Erasmus MC: University Medical Center Rotterdam

R Danesi, MDA Yerena-de Vega, M Oellerich, J Beck, S. Galbiati, M Del Re, … R.H.N. (Ron) van Schaik. (2021). What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? – Considerations on pre-analytical aspects by the IFCC workgroup cfDNA. Clinica Chimica Acta, 520, 168–171. doi:10.1016/j.cca.2021.05.033